• CureDuchenne Ventures will host Tevard Biosciences to present new preclinical data on suppressor tRNA therapy for Duchenne muscular dystrophy at the CureDuchenne FUTURES National Conference on May 22, 2026.
• A follow-on CureDuchenne webinar with Tevard is scheduled for May 28, 2026 at 12 p.m. PT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureDuchenne Ventures LLC published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.